1. Generics Bulletin
  2. >>Business

Teva Raises Guidance Amid Generics Growth

Firm Is Actively Examining BD Opportunities; Also Provides Update On Israel Conflict

 
• By Dave Wallace

Teva management sounded an optimistic note as the firm delivered its third-quarter results for 2023, adding a further $100m to the company’s full-year sales forecast and providing updates on a number of key aspects of the business.

Teva building
Teva has raised its guidance for 2023 • Source: Shutterstock

Buoyed by rising generics sales across all three of its geographical regions as well as higher turnover from branded assets such as Austedo (deutetrabenazine) and Ajovy (fremanezumab), Teva has hiked its full-year revenues forecast by $100m to a range of $15.1bn-$15.5bn.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

Roche Suggests Perjeta Biosimilars May Not Hit Until 2027 ‘Or Later’

 
• By Dean Rudge

Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By Adam Zamecnik

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.